NCT07401316 Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors
| NCT ID | NCT07401316 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | Germ Cell Cancer Metastatic |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2032-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 130 participants in total. It began in 2026-06-03 with a primary completion date of 2032-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.
Eligibility Criteria
Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Subjects must have histologically or serologically confirmed seminomatous or non seminomatous germ cell tumor. Non-seminoma includes embryonal carcinoma, choriocarcinoma, yolk sac tumor, or teratoma. Note: Cohort I is for high-risk clinical stage I disease (high risk will be defined as per enrolling investigator discretion). Cohort II is for clinical stage II. Cohort III is for clinical stage III or IS. 4. Archival tissue for germ-cell tumor diagnosis available Exclusion Criteria: 1. Concurrent disease or condition that would make the subject inappropriate for study participation 2. Any serious medical disorder that would interfere with the subject's safety 3. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent per treating physician coverage. 4. Patient is being tested for minimal residual disease with other experimental platforms
Contact & Investigator
Nabil Adra, MD
PRINCIPAL INVESTIGATOR
Indiana University
Frequently Asked Questions
Who can join the NCT07401316 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Germ Cell Cancer Metastatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07401316 currently recruiting?
Yes, NCT07401316 is actively recruiting participants. Contact the research team at marlmoor@iu.edu for enrollment information.
Where is the NCT07401316 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT07401316 clinical trial?
NCT07401316 is sponsored by Indiana University. The principal investigator is Nabil Adra, MD at Indiana University. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.